Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030484 · ClinicalTrials.gov registry record
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
A clinical trial, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- 2,501
- Enrollment target
NCT01030484: Completed study, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT01030484 is a clinical trial that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 2,501 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01030484 has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- 2,501 participants
- Enrollment target
Study Summary
The NAFLD Database 2 will recruit at least 1,500 new adult participants suspected or known to have NAFLD or nonalcoholic steatohepatitis (NASH)-related cirrhosis and will also invite adult participants from the prior NAFLD Database and related studies (PIVENS trial and TONIC trial) to enroll in the NAFLD Database 2. To elucidate, through the cooperative effort of a multidisciplinary and multicenter group of collaborators, the etiology, natural history, diagnosis, treatment, and prevention of NAFLD, and in particular its more severe form of NASH and its complications.
Primary Outcome
Liver histology scores (derived from central reading of liver biopsy at entry, standard of care biopsy done during screening or follow-up, or liver biopsy obtained for PIVENS or TONIC trials)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,501 participants |
| Start Date | 2009-12-02 |
| Est. Completion | 2020-05-31 |
What the finished NCT01030484 record still lists
NCT01030484 is an observational study that tracks outcomes without assigning an intervention. Its 2,501 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01030484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01030484 about?
NCT01030484 is a clinical study titled "Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2". The NAFLD Database 2 will recruit at least 1,500 new adult participants suspected or known to have NAFLD or nonalcoholic steatohepatitis (NASH)-related cirrhosis and will also invite adult participants from the prior NAFLD Database and related studies (PIVENS trial and TONIC trial) to enroll in the ...
What is the current status of trial NCT01030484?
This trial is currently completed. The enrollment target is 2,501 participants. The study started on 2009-12-02. Estimated completion is 2020-05-31.
Who is sponsoring clinical trial NCT01030484?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI